L1

L2

(FILE 'HOME' ENTERED AT 08:56:54 ON 30 JAN 2006)

INDEX 'ADISCTI, ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, ANTE, AQUALINE, AQUASCI, BIOENG, BIOSIS, BIOTECHABS, BIOTECHDS, BIOTECHNO, CABA, CAPLUS, CEABA-VTB, CIN, CONFSCI, CROPB, CROPU, DDFB, DDFU, DGENE, DISSABS, DRUGB, DRUGMONOG2, DRUGU, EMBAL, EMBASE, ...' ENTERED AT 08:57:07 ON 30 JAN 2006 SEA FIBROMYALGIA AND VACCINIA

- FILE BIOTECHABS 1
- 1 FILE BIOTECHDS
- 3 FILE CAPLUS
- 1 FILE DGENE
- 1 FILE EMBASE
- 2 FILE IFIPAT
- FILE JICST-EPLUS 1
- FILE PROMT 2
- FILE TOXCENTER 1
- 128 FILE USPATFULL
  - FILE USPAT2 4
  - FILE WPIDS
  - FILE WPINDEX

QUE FIBROMYALGIA AND VACCINIA

FILE 'CAPLUS' ENTERED AT 08:58:15 ON 30 JAN 2006 3 S FIBROMYALGIA AND VACCINIA

FILE 'WPIDS' ENTERED AT 09:00:26 ON 30 JAN 2006 L34 S FIBROMYALGIA AND VACCINIA

IN

```
L2
     ANSWER 1 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN
ΑN
     2005:238835 CAPLUS
DN
     142:309887
TI
     Use of poxvirus complement inhibiting proteins in treatment of rheumatic
     diseases
IN
     Kotwal, Girish J.; Jha, Purushottam
     University of Louisville Research Foundation, Inc., USA
PA
SO
     PCT Int. Appl., 49 pp.
     CODEN: PIXXD2
DT
     Patent
     English
LA
FAN.CNT 1
                        KIND
     PATENT NO.
                               DATE
                                           APPLICATION NO.
                                                                 DATE
                                           -----
     -----
                        ----
                               -----
                                                                  ------
ΡI
     WO 2005023296
                         A1
                               20050317
                                          WO 2004-US28936
                                                                  20040903
         W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
            CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
            GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
            LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
            NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
             TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
         RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
            AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
             EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,
             SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
             SN, TD, TG
PRAI US 2003-500666P
                          P
                               20030905
             THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE.CNT 8
              ALL CITATIONS AVAILABLE IN THE RE FORMAT
L2
     ANSWER 2 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN
AN
     2004:387330 CAPLUS
TI
     Remedy for fibromyalgia
IN
     Nishioka, Kusuki
PΑ
     Nippon Zoki Pharmaceutical Co., Ltd., Japan
so
     PCT Int. Appl.
     CODEN: PIXXD2
DT
     Patent
LA
     Japanese
FAN.CNT 1
     PATENT NO.
                        KIND
                               DATE
                                          APPLICATION NO.
     ______
                        ----
                               -----
                                           -----
                                                                  _____
PΙ
     WO 2004039383
                         A1
                               20040513
                                           WO 2003-JP13999
                                                                  20031031
            AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
            CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE,
            GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK,
            LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ,
            OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,
            TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
        RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,
            BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE,
            ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK,
            TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD,
     CA 2503810
                               20040513
                                           CA 2003-2503810
                         AΑ
                                                                  20031031
     EP 1566178
                               20050824
                                           EP 2003-770087
                         Α1
                                                                  20031031
            AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
            IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
PRAI JP 2002-317011
                               20021031
                         Α
     WO 2003-JP13999
                         W
                               20031031
RE.CNT 59
             THERE ARE 59 CITED REFERENCES AVAILABLE FOR THIS RECORD
             ALL CITATIONS AVAILABLE IN THE RE FORMAT
L2
    ANSWER 3 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN
AN
    2002:450339 CAPLUS
DN
     137:28294
TI
    LL-37 is an immunostimulant
```

Chertov, Oleg; Oppenheim, Joost J.; Yang, De; Anderson, Glenn M.; Wooters,

Joseph M.

PA USA

SO U.S. Pat. Appl. Publ., 12 pp.

CODEN: USXXCO

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
ΡI	US 2002072495	A1	20020613	US 2001-960876	20010921
	US 2004013679	A1	20040122	US 2003-619715	20030714
PRA	I US 2000-233983P	P	20000921		
	US 2001-960876	B1	20010921		

#### => d 12 1-3 ab

- L2 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN
- AB The present invention relates to the treatment of rheumatic diseases with a vaccinia virus complement control protein (VCP) or other poxvirus complement inhibiting proteins. In particular, it relates to treatment of osteoarthritis, rheumatoid arthritis, juvenile rheumatoid arthritis, fibromyalgia, systemic lupus erythematosus, scleroderma, spondyloarthropathy, ankylosing spondylitis, Reiter's syndrome, gout, infectious arthritis, Lyme disease, polymyalgia rheumatica, polymyositis, psoriatic arthritis, tendonitis, bursitis, and inflammation. The poxvirus complement inhibiting proteins are administered in a dosage of at least 25 mg/kg.
- L2 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN
- AB A remedy for fibromyalgia containing an extract of a tissue suffering from vaccinia virus inoculation-induced inflammation as the active ingredient, use of the extract of a tissue suffering from vaccinia virus inoculation-induced inflammation as the active ingredient for producing a medicinal composition for treating fibromyalgia, and a method of treating fibromyalgia which comprises administering a medicinal composition containing the extract of a tissue suffering from vaccinia virus inoculation-induced inflammation as the active ingredient to a patient. The remedy containing the extract of a tissue suffering from vaccinia virus inoculation-induced inflammation as the active ingredient is a novel remedy for fibromyalgia no efficacious remedy for which has been known so far. Moreover, it is highly useful as a highly safe and potent drug with scarcely any side effects.
- L2 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN
- AB The invention provides a method of enhancing an immune response in a subject, comprising administering an effective amount of LL-37. Moreover, the invention provides a method of enhancing in a subject an immune response to a vaccine, comprising administering to the subject an effective amount of LL-37 with a vaccine. Further provided is a method of detecting a compound that decreases an immune response in a subject. A method of treating an autoimmune disease in a subject is thus provided. Also provided is a vaccine comprising an immunogen and LL-37.

Welcome US PATENT & TRADEMARK OFFICE









home | issues | articles | reports | supplements | weblinks | conferences | glossary | search | information | subscribe | my details

#### **Arthritis Res Ther**

Volume 5 Suppl 3

#### Viewing options:

- Abstract
- Full text
- PDF (1,173KB)

#### Related literature:

① Other articles by authors

#### Tools:

- . E-mail to a friend
- Download references
- Post a comment

Poster presentation

## Clinical feature of fibromyalgia syndrome in Japan and novel strategy in the treatment by bioproduct (Neurotropin)

H Nakamura<sup>1</sup>, K Hoshi<sup>1</sup>, T Kato<sup>1</sup>, S Ozaki<sup>2</sup>, M Nishioka<sup>3</sup> and K Nishioka<sup>1</sup>

<sup>1</sup>Department of Bioregulation, Institute of Medical Science, St Marianna University, Kawasaki, Japan

<sup>2</sup>Department of Rheumatology, St Marianna University, Kawasaki, Japan <sup>3</sup>Jikei University School of Medicine, Tokyo, Japan

from 3rd World Congress of the Global Arthritis Research Network (GARN): International Arthritis Summit

Summit Hall at Sheraton Resorts in Miyazaki, Japan, 14-17 September 2003

Arthritis Res Ther 2003, 5(Suppl 3):170 doi:10.1186/ar971

**Published** 12 September 2003

**Purpose** 

Fibromyalgia syndrome (FMS) is a controversial disorder of unknown etiology. Because of lack of laboratory and objective findings, many patients have been ignored, misdiagnosed or referred to a psychiatrist. Recently, the number of FMS patients has been increasing in Japan. The purpose of this study is to elucidate the clinical feature of FMS and to evaluate the clinical efficacy of Neurotropin (extracted from inflammatory cutaneous tissue of rabbits inoculated with vaccinia virus) for FMS associated with neck or back pain.

#### Methods

Subjective complaints, tender points and clinical findings were assessed and routine laboratory examination was carried out in70 FMS patients. Among them, 23 patients were treated with Neurotropin, administered orally and intravenously. Patients' assessment and the number of tender points were evaluated after the treatment.

### **Results**

Subjective complaints were composed of fatigue, sleep disturbance, depression, anxiety and headache, as well as widespread pain. The mode of pain ranged from cutting pain to touch pain. In serious cases, patients could not even move the joints nor stand by their selves. Neurotropin treatment was effective in 16 out of 23 patients.

Further investigation will be needed to comprehend the present status of FMS in Japan and to elucidate its etiology. The effect of Neurotropin on FMS also needs to be evaluated.

90% of our authors would publish in a BioMed Central journal again Submit your paper now - click here >>>

**BioMed** Central The Open Access Publisher

Published

**BioWed** Central

© 1999-2006 BioMed Central Ltd unless otherwise stated < info@arthritis-research.com > Terms and conditions

Entered Medline: 19690725

L12 ANSWER 1 OF 2 MEDLINE on STN AN 83041979 MEDLINE DN PubMed ID: 6958083 [Local treatment of soft tissue rheumatism with a hemoderivative]. TIDie lokale Behandlung des "Weichteilrheumatismus" mit einem Hamoderivat. ΑU Manns K J Therapie der Gegenwart, (1982 Aug) 121 (8) 476-84. SO Journal code: 0413576. ISSN: 0040-5965. CY GERMANY, WEST: Germany, Federal Republic of Journal; Article; (JOURNAL ARTICLE) DTLAGerman Priority Journals FS ΕM 198212 Entered STN: 19900317 ED Last Updated on STN: 19900317 Entered Medline: 19821221 L12 ANSWER 2 OF 2 MEDLINE on STN AN69202165 MEDLINE DN PubMed ID: 4239331 ΤI Theoretical mechanism of production of the symptom stiffness. ΑU so Federation proceedings, (1969 May-Jun) 28 (3) 1073-9. Journal code: 0372771. ISSN: 0014-9446. CY United States DTJournal; Article; (JOURNAL ARTICLE) LA English Priority Journals FS EΜ 196907 ED Entered STN: 19900101 Last Updated on STN: 19970203


# **WEST Search History**



DATE: Monday, January 30, 2006

Hide? Set Name Query			Hit Count
	L26	'5560935'.pn.	1
	L25	'5658896'.pn.	1
	L24	'5807951'.pn.	1
	L23	"Neurotropin".clm.	18
	L22	Neurotropin.clm.	18
	L21	Neurotropin	168
	L20	'5227089'.pn.	1
	L19	'5127994'.pn.	1
	L18	'5560935'.pn.	. 1
	L17	'5057324'.pn.	1
	L16	'5057324'.pn.	1
	L15	'4985354'.pn.	. 1
	L14	'4985254'.pn.	1
	L13	'4863518'.pn.	1
	L12	'4138421'.pn.	1
	L11	'4089883'.pn.	1
	L10	'4056937'.pn.	1
	L9	'4039474'.pn.	1
	L8	'4036787'.pn.	1
	L7	'3959566'.pn.	1
	L6	'5560935'.pn.	1
	L5	'5013558'.pn.	1
	L4	extract and inflammatory tissue.clm.	6
	L3	extract and inflammatory tissue	171
	L2	extract from inflammatory tissue	0
	L1	6165515	3

END OF SEARCH HISTORY



	Y, Okudaira H.  [Inhibitory effect of histamine-added mouse gamma-glo accumulation induced by allergen in BALB/c mice]  Arerugi. 1995 May;44(5):567-70. Japanese.  PMID: 7542444 [PubMed - indexed for MEDLINE]	obulin on eosinophil			
□ 7:	Shimada T, Cheng L, Ide M, Fukuda S, Enomoto T, Shirakawa T.				
	Effect of lysed Enterococcus faecalis FK-23 (LFK) on a peritoneal accumulation of eosinophils in mice. Clin Exp Allergy. 2003 May;33(5):684-7. PMID: 12752599 [PubMed - indexed for MEDLINE]	allergen-induced			
□ 8:	Gelfand EW, Cui ZH, Takeda K, Kanehiro A, Joetham A.	Related Articles, Links			
	Effects of fexofenadine on T-cell function in a murine model of allergen- induced airway inflammation and hyperresponsiveness. J Allergy Clin Immunol. 2003 Oct;112(4 Suppl):S89-95. PMID: 14530794 [PubMed - indexed for MEDLINE]				
□9:	Yanagihara Y, Shida T, Yoshii H.	Related Articles, Links			
	[Immunopharmacological actions of neurotropin. (1). In actions of neurotropin (author's transl)] Nippon Yakurigaku Zasshi. 1981 Nov;78(5):439-49. Japanese. PMID: 7327458 [PubMed - indexed for MEDLINE]	nmunostimulating			
□ 10	Penido C, Castro-Faria-Neto HC, Larangeira AP, Rosas EC, Ribeiro-dos-Santos R, Bozza PT, Henriques MG.	Related Articles, Links			
	The role of gammadelta T lymphocytes in lipopolysac eosinophil accumulation into the mouse pleural cavity J Immunol. 1997 Jul 15;159(2):853-60. PMID: 9218604 [PubMed - indexed for MEDLINE]				
□ 11	Lagente V, Carre C, Kyriacopoulos F, Boichot E, Mencia-Huerta JM, Braquet P.	Related Articles, Links			
	Inhibitory effect of cyclosporin A on eosinophil infiltration in the guineapig lung induced by antigen, platelet-activating factor and leukotriene B4. Eur Respir J. 1994 May;7(5):921-6. PMID: 8050549 [PubMed - indexed for MEDLINE]				
□ 12	: Kawamura M, Ohara H, Go K, Koga Y, Ienaga K.	Related Articles, Links			
	Neurotropin induces antinociceptive effect by enhanci inhibitory systems involving 5-HT3 and noradrenergic spinal dorsal horn. Life Sci. 1998;62(24):2181-90. PMID: 9627076 [PubMed - indexed for MEDLINE]	•			
□ 13	: Zuany-Amorim C, Leduc D, Vargaftig BB, Pretolani M.	Related Articles, Links			
	Characterization and pharmacological modulation of a peritonitis in actively sensitized mice. Br J Pharmacol. 1993 Oct;110(2):917-24. PMID: 7694762 [PubMed - indexed for MEDLINE]	ntigen-induced			
□ 14	: Teixeira MM, Williams TJ, Hellewell PG.	Related Articles, Links			
Effects of dexamethasone and cyclosporin A on the accumulation of eosinophils in acute cutaneous inflammation in the guinea-pig.					

	Br J Pharmacol. 1996 May;118(2):317-24. PMID: 8735633 [PubMed - indexed for MEDLINE]	
□ 15:	Bozza PT, Castro-Faria-Neto HC, Penido C, Larangeira AP, das Gracas M, Henriques MO, Silva PM, Martins MA, dos Santos RR, Cordeiro RS.	Related Articles, Links
	Requirement for lymphocytes and resident macrophage pleural eosinophil accumulation.  J Leukoc Biol. 1994 Aug;56(2):151-8.  PMID: 8071592 [PubMed - indexed for MEDLINE]	es in LPS-induced
□ 16:	Kato S, Nakamura H, Naiki M, Takeoka Y, Suehiro S.	Related Articles, Links
	Suppression of acute experimental allergic encephalor neurotropin: clinical, histopathologic, immunologic ar immunohistochemical studies.  J Neuroimmunol. 1991 Dec;35(1-3):237-45. PMID: 1955567 [PubMed - indexed for MEDLINE]	•
□ 17:	Corry DB, Grunig G, Hadeiba H, Kurup VP, Warnock ML, Sheppard D, Rennick DM, Locksley RM.	Related Articles, Links
	Requirements for allergen-induced airway hyperreacticell-deficient mice. Mol Med. 1998 May;4(5):344-55. PMID: 9642684 [PubMed - indexed for MEDLINE]	vity in T and B
□ 18:	Kaneko M, Hitoshi Y, Takatsu K, Matsumoto S.	Related Articles, Links
	Role of interleukin-5 in local accumulation of eosinop allergic peritonitis. Int Arch Allergy Appl Immunol. 1991;96(1):41-5. PMID: 1752694 [PubMed - indexed for MEDLINE]	hils in mouse
□ 19:	Yanagihara Y, Shida T, Yoshii H.	Related Articles, Links
	[Immunopharmacological actions of neurotropin. (2). neurotropin on graft-versus-host reaction (author's tran Nippon Yakurigaku Zasshi. 1981 Nov;78(5):451-8. Japanese. PMID: 7327459 [PubMed - indexed for MEDLINE]	
□ 20:	Bauer L, Bohle B, Jahn-Schmid B, Wiedermann U, Daser A, Renz H, Kraft D, Ebner C.	Related Articles, Links
	Modulation of the allergic immune response in BALB subcutaneous injection of high doses of the dominant the major birch pollen allergen Bet v 1. Clin Exp Immunol. 1997 Mar;107(3):536-41. PMID: 9067529 [PubMed - indexed for MEDLINE]	
I	tems 1 - 20 of 126	1 of 7 Next
Display	Summary Show 20 Sort by Ser	nd to

Write to the Help Desk

NCB! | NLM | NIH

Department of Health & Human Services

Privacy Statement | Freedom of Information Act | Disclaimer

Jan 19 2006 04:31:52